ILSI/HESI maternal toxicity workshop summary: Maternal toxicity and its impact on study design and data interpretation

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 92, Issue 1, 2011, Pages 36-51

  Beyer, Bruce K ^a   Chernoff, Neil ^b   Danielsson, Bengt R ^c,d   Davis Bruno, Karen ^e   Harrouk, Wafa ^e   Hood, Ronald D ^f,g   Janer, Gemma ^h   Liminga, Ulla Wändel ⁱ   Kim, James H ^j   Rocca, Meredith ^k   Rogers, John ^b   Scialli, Anthony R ^l  

^a Department of Disposition   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c Pharmanet Development Group   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF ALABAMA   (United States)

^g Toxicology Consultants   (United States)

^h Palau Pharma SA   (Spain)

ⁱ MEDICAL PRODUCTS AGENCY   (Sweden)

^j ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^k ELAN PHARMACEUTICALS   (United States)

^l Tetra Tech Sciences   (United States)

more..

Author keywords

Developmental toxicity; Maternal toxicity; Maternal fetal interactions; Mechanisms of teratogenesis; Pharmaceuticals; Prenatal; Safety assessment; Teratology

Indexed keywords

ACETAZOLAMIDE; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; CLOMIPRAMINE; CONATUMUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; IMIPRAMINE; INDACRINONE; LENALIDOMIDE; MEVINOLIN; NATALIZUMAB; NORFLOXACIN; PALIFERMIN; PHENYTOIN; POTASSIUM CHANNEL HERG; ROMIPLOSTIM; TELITHROMYCIN;

ARTICLE; BIOASSAY; BODY WEIGHT; BRADYCARDIA; CLEFT LIP PALATE; CLINICAL EVALUATION; COMPETITIVE INHIBITION; CONGENITAL MALFORMATION; CYSTIC FIBROSIS; DATA ANALYSIS; DEVELOPMENTAL DISORDER; DIETARY INTAKE; DRUG SURVEILLANCE PROGRAM; ECTRODACTYLY; EMBRYO DEATH; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; ENVIRONMENTAL EXPOSURE; FETAL ALCOHOL SYNDROME; FETAL WELL BEING; FETUS MALFORMATION; FETUS OUTCOME; FETUS WEIGHT; FOLLOW UP; GESTATION PERIOD; HYPERLIPIDEMIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL MORTALITY; MATERNAL SMOKING; MATERNAL TOXICITY; MEDICAL SOCIETY; MOTHER FETUS RELATIONSHIP; NONHUMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; QT PROLONGATION; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET ORGAN; TERATOGENESIS; TERATOGENICITY; TERATOLOGY; TOXICITY; TOXICITY TESTING; WEIGHT GAIN; WORKSHOP;

ANIMALS; BODY WEIGHT; EMBRYONIC DEVELOPMENT; FEMALE; FETUS; HUMANS; MATERNAL EXPOSURE; MICE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RABBITS; RATS; RESEARCH DESIGN; STATISTICS AS TOPIC; TOXICITY TESTS;

ANIMALIA;

EID: 79751472356     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20281     Document Type: Article

References (74)

1. Abrahamsson C, Palmer M, Ljung B, et al. 1994. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res28:337-344.
2. Cappon GD, Fleeman TL, Chapin RE, Hurtt ME. 2005. Effects of feed restriction during organogenesis on embryo-fetal development in the rabbit. Birth Defects Res B Dev Reprod Toxicol74:424-430.
3. Chernoff N, Setzer RW, Miller DB, et al. 1990. Effects of chemically induced maternal toxicity on prenatal development in the rat. Teratology42:651-658.
4. Chernoff N, Rogers EH, Gage MI, Francis BM. 2008. The relationship of maternal and fetal toxicology bioassays with notes on the biological significance of the "no observed adverse effect level". Reprod Toxicol25:192-202.
5. Christian MS, Laskin OL, Sharper V, et al. 2007. Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol80:188-207.
6. Clark RL, Robertson RT, Minsker DH, et al. 1984. Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits. Teratology30:319-332.
7. Clark RL, Robertson RT, Peter CP, et al. 1986. Association between adverse maternal and embryo-fetal effects in norfloxacin-treated and food-deprived rabbits. Fundam Appl Toxicol7:272-286.
8. Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances.
9. Danielsson BR, Reiland S, Rundqvist E, Danielson M. 1989. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology40:351-358.
10. Danielsson BR, Danielson M, Reiland S, et al. 1990. Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators. Teratology41:185-193.
11. Danielsson MK, Danielsson BR, Marchner H, et al. 1992. Histopathological and hemodynamic studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity. Teratology46:485-497.
12. Danielsson BR, Sköld AC, Johansson A, et al. 2003. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol193:68-176.
13. Danielsson BR, Hohansson A, Danielsson C, et al. 2005. Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism. Birth Defects Res A Clin Mol Teratol73:46-153.
14. Krblocking drugs. Reprod Toxicol24:42-56.
15. European Public Assessment Report on revlimid. August 14, 2008; updated May 17, 2010. Available at.
16. Fawcett LB, Buck SJ, Brent RL. 1998. Limb reduction defects in the A/J mouse strain associated with maternal blood loss. Teratology58:183-189.
17. Fleeman TL, Cappon GD, Chapin RE, Hurtt ME. 2005. Effects of feed restriction during organogenesis on embryo-fetal development in the rat. Birth Defects Res B Dev Reprod Toxicol74:42-49.
18. Franklin JB, Brent RB. 1964. The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old. J Morphol115:273-290.
19. Garofano A, Czernichow P, Breant B. 1998. Postnatal somatic growth and insulin contents in moderate or severe intrauterine growth retardation in the rat. Biol Neonate73:89-98.
20. Grabowski C. 1970. Embryonic oxygen deficiency-a physiological approach to analysis of teratological mechanisms. In: Woollam DHM, editor. Advances in teratology. Vol. 9. London: Logos Press Ltd. p 125-169.
21. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, M3(R2).International Conference on Harmonization (ICH). Step 4 version, June 11, 2009.
22. Guidance to Industry: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility, S5(R2). International Conference on Harmonization (ICH). Amended Step 5 version, November 2005.
23. Hales CN, Barker DJ, Clark PM, et al. 1991. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J303:1019-1022.
24. Hansen D, Lou HC, Olsen J. 2000. Serious life events and congenital malformations: a national study with complete follow-up. Lancet356:875-880.
25. He J-Q, Ma Y, Lee Y, et al. 2003. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res93:32-39.
26. Hood RD, Miller DB. 2006. Maternally mediated effects on development. In: Hood RD, editor. Developmental and reproductive toxicology, a practical approach. 2nd ed. Boca Raton: CRC Press. p 93-124.
27. Hurtt ME, Cappon GD, Browning A. 2003. Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food-producing animals. Food Chem Toxicol41:611-619.
28. Jaeggi E, Laskin C, Hamilton R, et al. 2010. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol55:2778-2784.
29. Källen B, Otterblad Olausson P. 2006. Antidepressant drugs during pregnancy and infant congenital heart defects. Reprod Toxicol21:221-222.
30. Källen BA, Otterblad Olausson P, Danielsson BR. 2005. Is erythromycin therapy teratogenic in humans?Reprod Toxciol20:209-214.
31. Kr-blocking activity to determine their teratogenic potential. Curr Pharm Des13:2979-2988.
32. Kavlock RJ, Chernoff N, Rogers EH. 1985. The effect of acute maternal toxicity on fetal development in the mouse. Teratog Carcinog Mutagen5:3-13.
33. Khera KS. 1984. Maternal toxicity-a possible factor in fetal malformations in mice. Teratology29:411-416.
34. Khera KS. 1985. Maternal toxicity: a possible etiological factor in embryo-fetal death and fetal malformation of rodent-rabbit species. Teratology31:129-153.
35. Khera KS. 1987. Maternal toxicity in humans and animals: effects on fetal development and criteria for detection. Teratog Carcinog Mutagen7:287-295.
36. Klinger G, Merlob P. 2009. SSRIs and heart defects in neonates. Br Med J339:b4288.
37. Langley-Evans SC. 2006. Developmental programming of health and disease. Proc Nutr Soc65:97-105.
38. Lederman SA, Rosso P. 1981. Effects of obesity, food restriction and pregnancy on fetal and maternal weight and on body composition in rats. J Nutr111:2162-2171.
39. Leguizamón G, Igarzabal ML, Reece EA. 2007. Periconceptional care of women with diabetes mellitus. Obstet Gynecol Clin North Am34:225-239.
40. Marks TA, Terry RD. 1996. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratolgoy54:157-164.
41. Martin PL, Breslin W, Rocca M, et al. 2009. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B Dev Reprod Toxicol86:167-203.
42. Matuzawa T, Nakata M, Goto I, Tsushima M. 1981. Dietary deprivation induces fetal loss and abortion in rabbits. Toxicol22:255-259.
43. Merlob P, Birk E, Sirota L, et al. 2009. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol85:837-841.
44. Nilsson MF, Danielsson C, Sköld AC, et al. 2010. Astemizole: Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reprod Toxicol29:156-163; Epub 2010 Feb 6.
45. Organization for Economic Cooperation and Development (OECD).2001. OECD Test Guideline for the Testing of Chemicals. 414 Prenatal Developmental Toxicity Study. Available at.
46. Organization for Economic Cooperation and Development (OECD).2007. Draft guidance document on mammalian reproductive toxicity testing and assessment. OECD Environment, Health and Safety Publications, Series on Testing and Assessment, No. 43. Available at.
47. Painter RC, Roseboom TJ, Bleker OP. 2005. Prenatal exposure to the Dutch famine and disease in later life: an overview. Reprod Toxicol20:345-352.
48. Petrere JA, Rohn WR, Grantham LE, Anderson JA. 1993. Food restriction during organogenesis in rabbits: effects on reproduction and the offspring. Fundam Appl Toxicol21:517-522.
49. Podymow T, August P. 2007. Hypertension in pregnancy. Adv Chronic Kidney Dis14:178-190.
50. Polak S, Wisnowska B, Brandys J. 2009. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. Appl Toxicol29:183-206.
51. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.
52. Rogers JM, Chernoff N, Keen CL, Daston GP. 2005. Evaluation and interpretation of maternal toxicity in Segment II studies: issues, some answers, and data needs. Toxicol Appl Pharmacol207:S267-S374.
53. Rooseboom T, de Rooij S, Painter R. 2006. The Dutch famine and its long-term consequences for adult health. Early Hum Dev82:485-491.
54. Schardein JL. 2000. Chemically induced birth defects. 3rd ed. New York: Marcel Dekker, Inc.
55. Sköld AC, Danielsson BR. 2000. Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Adverse effects mediated via induction of embryonic heart rhythm abnormalities. Arzneimittel-Forchung50:520-525.
56. Sköld AC, Danielsson BR. 2001. Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol. Pharmacol Toxicol88:34-39.
57. Kr-blocker almokalant: further evidence for teratogenicity via a hypoxia-related mechanism. Teratology64:292-300.
58. Kr-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol16:333-342.
59. Smith CA. 1947. The effect of wartime starvation in Holland upon pregnancy and its product. Am J Obstet Gynecol53:599-608.
60. Smyth A, Oliveira GH, Lahr BD, et al. 2010. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol0:CJN.00240110v1-CJN.00240110.
61. Solomon HM, Wier PJ, Fish CJ, et al. 1997. Spontaneous and induced alterations in the cardiac membranous ventricular septum of fetal, weanling, and adult rats. Teratology55:185-194.
62. Spence SG, Vetter C, Hoe C-M. 1994. Effects of the class III antiarrhythmic dofetilide (UK-68, 798) on the heart rate of midgestation rat embryos, in vitro. Teratology49:282-292.
63. Stein AD, Ravelli AC, Lumey LH. 1995. Famine, third-trimester pregnancy weight gain, and intrauterine growth: The Dutch Famine Birth Cohort Study. Hum Biol67:135-150.
64. US Environmental Protection Agency (EPA).1991. Guidelines for developmental toxicity risk assessment. Fed Regist56:63798-63826.
65. US Environmental Protection Agency (EPA).1998. Health effects test guidelines. OPPTS 870.3700. Prenatal Developmental Toxicity Study. Available at.
66. US Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition.2000. Toxicological principles for the safety assessment of food ingredients. Chapter IV.C.9.b. Guidelines for Developmental Toxicity Studies, Redbook 2000.
67. Vickers MH, Breier BH, Cutfield WS, et al. 2000. Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nuturition. Am J Physiol Endocrinol Metab279:E83-E87.
68. +channels in mouse heart. Circ Res79:79-85.
69. Webster WS, Abela D. 2007. The effect of hypoxia in development. Birth Defects Res C Embryo Today81:215-228.
70. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR. 1996. Teratogenic potential of almokalant, dofetilide, and d-dotalol: drugs with potassium channel blocking activity. Teratology53:168-175.
71. Wehner NG, Shopp G, Oneda S, Clarke J. 2009. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol86:117-130.
72. Weintrob N, Karp M, Hod M. 1996. Short- and long-range complications in offspring of diabetic mothers. J Diabetes Complicat10:294-301.
73. Wellfelt K, Sköld AC, Wallin A, Danielsson BR. 1999. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod Toxicol13:93-101.
74. Yoshida T, Kanamori S, Hasegawa Y. 1988. Hyperphalangeal bones induced in rat pups by maternal treatment with nifedipine. Toxicol Lett40:127-132.